Skip to main
BLTE

BLTE Stock Forecast & Price Target

BLTE Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Belite Bio is well-funded with $772.6M in cash and investments, which is sufficient to complete the FDA regulatory process, commercially launch tinlarebant, and continue ongoing clinical trials. This financial stability, along with a strong pipeline and favorable probabilities of approval for their product candidates, makes Belite Bio a promising investment opportunity with potential for significant growth. However, there are risks to consider, such as potential failure in clinical trials or securing regulatory approval, and competition in the market.

Bears say

Belite Bio is expected to complete a rolling submission of a New Drug Application (NDA) for tinlarebant, its novel oral therapy for Stargardt disease type 1 (STGD1), by the end of 2026, and potentially obtain FDA approval by the end of 2026. The company's planned sales team of 25-30 personnel will focus on genetic testing awareness to identify the estimated 53,000 U.S. patients with ABCA4-mutated STGD1, potentially allowing for a broad label for all patients above 12 years of age with similar genetic pathology. However, given the clinical stage of Belite Bio and the competitive landscape for degenerative retinal disease treatments, we believe there is considerable risk for delays in FDA approval and commercial success.

BLTE has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Belite Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Belite Bio Inc (BLTE) Forecast

Analysts have given BLTE a Buy based on their latest research and market trends.

According to 6 analysts, BLTE has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $198, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $198, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Belite Bio Inc (BLTE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.